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Purpose: Building on previous research, we examined whether delayed study start
and low patient accrual rates found in 31 postauthorization registry‐based studies
requested by European Medicines Agency (EMA) are maintained after 2 additional
years of follow‐up.
Method: The registries identified in the previous EMA study and the same method-
ology were used. The follow‐up was extended from June 2015 to November 2017.
The information available for the following variables was updated: marketing authori-
zation status, study and registry status, study end date, planned duration, number of
patients planned to be enrolled, and actual patients enrolled. Data were collected
from several nonpublic in‐house sources such as the study protocols, interim and final
study reports, risk management plans, and periodic safety update reports.
Results: As of November 2017, 10 (32.2%) studies were finalized (vs. 9.7% as of
June 2015), 14 (45.2%) were still ongoing (vs. 64.5%). Four of the ongoing studies
had patients' accrual lower than 50%. Six of the finalized studies had a delayed com-
pletion, with a median delay of 3 years. As of November 2017, the median patients'
accrual percentages were 24% for ongoing studies (vs. 8.5%) and 101% for finalized
studies (vs. 24%).
Conclusion: Overall, the rate of recruitment and timely finalization were improved
after 2 years of additional follow‐up but show that further work is needed to facilitate
use of registry data for regulatory purposes, a work that has started via the EMA reg-
istry initiative.1 | BACKGROUND AND PREVIOUS
FINDINGS
Postauthorization studies based on patient registries are frequently
requested to marketing authorization holders by regulatory authorities
to support the benefit‐risk monitoring of their licensed drugs.1-3 A
previous European Medicines Agency (EMA) study examined the char-
acteristics of registries imposed by EMA as a legally binding condition
of the marketing authorization.1 Of a total of 392 products that
received a positive opinion for a marketing authorization from the
EMA Committee for Human Medicinal Products between January 1,wileyonlinelibrary.com/jou2005 and December 31, 2013, 31 registry‐based studies had been
imposed for 30 products (7.6%). By June 2015, approximately 25%
of these imposed studies had not started, 50% were ongoing, and less
than 10% had been completed. The issues most commonly identified
by the EMA in this review were delayed time to start and low patient
accrual rates. Based on these results, the EMA recommended the use
of existing patient registries to improve the timeliness of data collec-
tion in the postmarketing setting.
The current study examines whether these critical issues still
apply to the 31 registry‐based studies after a longer observation
period (follow‐up extended by 2 years until November 30, 2017).Copyright © 2018 John Wiley & Sons, Ltd.rnal/pds 1
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patient registries that aim to make better use of existing registries
for regulatory purposes.42 | METHODS
The list of registries identified in the previous EMA study and the same
methodology were used in this study. The information available for the
following variables was updated: marketing authorization status, study
and registry status, study end date, planned duration and number of
patients planned to be enrolled, and actual patients enrolled. These data
were collected from several combined nonpublic in‐house sources such
as study protocols, interim and final study reports, risk management
plans, and periodic safety update reports.
As discussed, in the initial study, the terms “registry” and “study”
are sometimes used interchangeably. In this follow‐up study, we dis-
tinguished between the situation in which regulators specificallyTABLE 1 Study and registry statuses over time (n = 31)
Registry Status
January 2005‐June 2015a
January 2005
2017
N (%) N (%)
Not startedb 7 (22.6%) 5 (16.1%)
Ongoing 20 (64.5%) 10 (32.3%)
Finalized 3 (9.7%) 10 (32.3%)
Missing informationc 1 (3.2%) 1 (3.2%)
Open endedd N/A 5 (16.1%)
aFor the period between January 2005 and June 2015, the registry and study
differentiate between these 2 terms.
bAll the studies/registries in the “not started” category are related to products
cMissing information about the end date/study status.
dThe registries are run independently from the conduct of the studies.
FIGURE 1 Accrual percentage in relation to study progression status. Ea
bars: The light gray bar represents the study progression status, and the b
“progression” above 100% are running longer than planned [Colour figureimposed a requirement to establish a registry as a systematic data col-
lection tool and the situation in which a specific postauthorization
study was imposed with specific objectives and a study design involv-
ing the use of a registry as the data collection tool.4
To illustrate the progress of the studies, we defined the “patient
accrual percentage” as the number of patients currently enrolled in
the study divided by the number of planned patients, and the “study
progression status” as actual study duration (from first patient enrolled
until last date of data collection) divided by the planned study
duration.3 | RESULTS
3.1 | Study status
As of November 2017, 6 studies (19.4%) had not yet started recruiting
patients (as compared with 7 as of June 2015) and 10 studies (32.2%)Study Status
‐November January 2005‐June
2015
January 2005‐November
2017
N (%) N (%)
7 (22.6%) 6 (19.4%)
20 (64.5%) 14 (45.2%)
3 (9.7%) 10 (32.2%)
1 (3.2%) 1 (3.2%)
N/A N/A
status are identical, as the first European Medicines Agency study did not
for which the marketing authorizations have been withdrawn.
ch number on x‐axis represents a different study and is described by 2
lack bar represents patient accrual percentage. Studies with
can be viewed at wileyonlinelibrary.com]
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studies were still ongoing (45.2%), compared with 20 (64.5%) in the
previous period (see Table 1).
For 11 of the 14 ongoing studies and for 8 of the 10 finalized
studies, available information allowed to calculate either study pro-
gression status or accrual percentage (Figure 1). Among the ongoing
studies, 4 were still within the original agreed timeframe (progression
status <100%) with 1 study already surpassing the targeted number
of patients, and 5 were delayed by a median of 5 years (range: 1‐
7 years) with patients' accrual lower than 50% for 4 of them (1 had
missing data). Among the finalized studies, 6 had a delayed completion
with a median delay of 3 years (range: 2‐6 years). Three finalized stud-
ies managed to reach or surpass 100% of patients' accrual.
Fifty percent of studies conducted within disease registries and
33% of studies conducted within product registries were delayed
compared with the planned finalization date.
As of November 2017, the median patients' accrual percentages
were 24% for ongoing studies and 101% for finalized studies, as com-
pared with 8.5% and 24% in June 2015.3.2 | Registry status
Compared with the previous period, 2 (6.4%) more registries started
data collection and 7 (22.6%) more were finalized. Five registries
(16%) are open‐ended (Table 1).
Both for studies and registries, missing data were common,
highlighting an omission to report essential information to regulators.
The following variables were most affected: planned duration (26%
missing data), planned patients (9.7% missing data), number of actual
patients, and study end date (6.5% missing data).4 | DISCUSSION AND CONCLUSION
This update shows that 32.2% of registry‐based studies were finalized
as of November 2017 as compared with 9.7% as of June 2015. The
overall patient accrual was higher than in the first period, both for
ongoing and finalized studies.
Overall, the conclusions reached in the initial EMA study remain
valid after a longer follow‐up period: Both the rate of recruitment and
timely finalization are challenging for registry‐based studies. A reason
may be that most of the investigated products are orphan or specialized
products with a very small target population. This should be taken into
consideration during the study design stage when realistic study
timeframes and planned patient numbers should be proposed.
Althoughseveral nonpublic data sourceswereconsulted, consistent
informationonplannedduration, planned/actual patients, and studyend
date was still difficult to identify. The current results therefore support
the need for more systematic, transparent, and standardized approach
for the conduct and reporting of registry‐based studies. It should be
highlighted that most of the studies identified in the initial study were
imposed before the new EU pharmacovigilance legislation took effect
in July 2012.5 The new legislation requires the review of the study pro-
tocols and results by the Pharmacovigilance and Risk Assessment Com-
mittee and the registration of imposed postauthorization safety studiesin the EU PAS Register.6 These measures should, at least in theory, lead
to an improvement in reporting. An evaluation of registry‐based studies
imposed after July 2012 should identify whether improvements have
beenmade following the newEUpharmacovigilance legislation, and this
may be an area of future research for EMA.
Most registries used for imposed studies in this review are prod-
uct registries, with patient entry based on exposure to a specific drug.
The EMA's Patient Registries Initiative initiated in 20154 strongly rec-
ommends use of “disease registries,” covering a wider population
defined by a particular condition that is followed over time regardless
of the products administered. As disease registries are generally inte-
grated in health systems and clinical practice, they may be associated
with better accesibility to data.
European Medicines Agency is already aware of the challenges in
using registries to monitor the safety of marketed medicines. To this
end, EMA has held 2 specific registry workshops on cystic fibrosis
and multiple sclerosis diseases.7,8 The analysis performed at these
workshops highlighted that registries do not often collect routinely
all the data needed for a postauthorization study. This may be due
to the limited standardization of data elements captured by national
and international registries, the inadequate data quality control, the
time lag between the data collection and data availability, as well as
a possible misunderstanding by regulators of the ability of a given
registry to collect data on specific regulatory concerns. These aspects
are currently being addressed through the EMA initiative for patient
registries focusing on efficient collaboration among medicine regula-
tors, pharmaceutical companies, and various registry coordinators. A
certification process could ensure users that the data are of accept-
able quality for regulatory purposes. As a first example in this
direction, the European Cystic Fibrosis Society Patient Registry9
undertook an EMA qualification procedure to assess whether its' data
collection system is adequate to support regulatory decision
making.10
Overall, the data from this report are encouraging but show that
further work are needed to facilitate use of registry data for regulatory
purposes, a work that has already been started via the EMA registry
initiative.
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